Bayern Nordic is making “every effort” to meet demand for monkeypox vaccine. Monkeypox vaccine is the only approved shot against the rapidly spreading disease, and countries are severely limited in supply.
Danish biotech company CEO Paul Chaplin said on Wednesday that the outbreak was “unprecedented” as the company announced its first-half results.
“We are making every effort to meet the initial global demand for the monkeypox vaccine and are working diligently to further expand our manufacturing capacity through additional scale-up activities and partnerships.” he said.
Bayern said last week it had signed a limited deal with a US manufacturer to expand supply.
41,000+ monkeypox Cases have been detected since May, when an outbreak was reported in Europe. Prior to this epidemic, monkeypox was endemic in sub-Saharan Africa. The numbers aren’t definitive, but there are early signs that global spread may be slowing.
The shot known as Jynneos or Imvanex is in very limited supply. It was kept in large stockpiles just in case. Later, authorities approved it for use against monkeypox, a virus very similar to smallpox.
England We’re almost out of supplies As the Financial Times reported, no more will be available until late September, and other parts of Europe are also grappling with shortages. We advocate “divided doses” (administering part of the usual dose).
Also on Wednesday, Bayern said it had signed a deal with the World Health Organization’s Pan American Health Organization to increase access to shots in Latin America and the Caribbean, with deliveries expected to begin in September.
Bavaria said on Wednesday it posted a loss before interest, tax, depreciation and amortization of DKr 212 million ($28 million) on earnings of DKr 857 million in the first half.
The company has raised its guidance six times since March, buoyed by vaccine orders.
Analysts at Citi said they expected “large second-half monkeypox vaccine orders to significantly change the earnings outlook for Bavaria for 2023, 2024 and 2025”.
Citi added that confirmed orders for 2022 exceeded 2 million and are fast approaching 8 million for 2023.
Bavarian Nordic rushes to ramp up production of monkeypox vaccine
Source link Bavarian Nordic rushes to ramp up production of monkeypox vaccine
The post Bavarian Nordic rushes to ramp up production of monkeypox vaccine appeared first on Eminetra.